Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.
Advancing knowledge in the field of heart failure management
The European Journal of Heart Failure (EJHF) is dedicated to the advancement of knowledge in the field of heart failure management.
The journal publishes reviews and editorials to improve the understanding, prevention, investigation and treatment of heart failure. Molecular and cellular biology, pathology, physiology, electrophysiology, pharmacology, as well as clinical, social and population sciences all form part of the discipline.
European Journal of Heart Failure Top reviewers 2024
Fast Facts
Editor-in-Chief: Michael Böhm (DE)
Current volume: 27 (year 2025)
Issues per subscription: 12
Impact Factor 2024: 10.8
Editor-in-chief History
Name
Start Date
End Date
Professor John Cleland
01/01/1999
31/12/2004
Professor Karl Swedberg
01/01/2005
31/12/2009
Professor Dirk J. Van Veldhuisen
01/01/2010
31/12/2014
Professor Marco Metra
01/01/2015
31/03/2024
Professor Michael Böhm
01/04/2024
Member Benefits
HFA Members can benefit from discounted or free online access and a print subscription to the European Journal of Heart Failure.
New: Healthcare professionals practicing in low and lower-middle income countries (World Bank classification) are now eligible for a reduced Membership rate.
Why healthcare providers' adherence to guideline‐directed medical therapy is only half the battle
Author(s):
Martin Schulz,
Felix Mahfoud,
Ulrich Laufs
28 Nov 2025
Pharmacological treatment for patients with obesity and heart failure: Focus on glucagon‐like peptide‐1 receptor agonists. European Journal of Heart Failure expert consensus document
Author(s):
Luca Monzo,
Gianluigi Savarese,
Wilfried Mullens,
Amr Abdin,
Biykem Bozkurt,
Ovidiu Chioncel,
Seif El Hadidi,
Thomas M. Gorter,
Riccardo M. Inciardi,
Mark C. Petrie,
Gabriele G. Schiattarella,
Davide Stolfo,
Marco Metra,
Nicolas Girerd
29 Nov 2025
Clinical phenotype and prognosis of real‐world patients with wild‐type transthyretin amyloid cardiomyopathy treated with tafamidis
Author(s):
Aldostefano Porcari,
Paolo Milani,
Simone Longhi,
Francesco Cappelli,
Fabio Vagnarelli,
Alberto Aimo,
Alberto Cipriani,
Elisa Gardini,
Stefania Marazia,
Emanuele Monda,
Giacomo Tini,
Beatrice Musumeci,
Matteo Serenelli,
Anna Cantone,
Carla Lofiego,
Marco Marini,
Giuseppe Vergaro,
Grazia Foti,
Francesco Musca,
Daniela Tomasoni,
Giacomo Bonacchi,
Federica Colio,
Giulio Sinigiani,
Laura De Michieli,
Francesca Sturdà,
Marco Pozzan,
Piero Gentile,
Samuela Carigi,
Michela Bartolotti,
Giuseppe Sena,
Irene Ruotolo,
Giuseppe Damiano Sanna,
Margherita Zanoletti,
Marco Canepa,
Massimo Di Marco,
Emilia D'Elia,
Gianluca Di Bella,
Mauro Driussi,
Massimo Imazio,
Federico Perfetto,
Elena Biagini,
Giuseppe Limongelli,
Marco Metra,
Michele Emdin,
Giampaolo Merlini,
Stefano Perlini,
Marco Merlo,
Giovanni Palladini,
Gianfranco Sinagra
26 Nov 2025
Effects of semaglutide in obesity‐related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP‐HFpEF programme
Author(s):
Ambarish Pandey,
Michael Moroney,
Subodh Verma,
Barry A. Borlaug,
Javed Butler,
Melanie J. Davies,
Dalane W. Kitzman,
Sanjiv J. Shah,
Mark C. Petrie,
Cecilia Rönnbäck,
Anne Domdey,
Søren Rasmussen,
Khaja M. Chinnakondepalli,
Shachi Patel,
Mikhail N. Kosiborod
Our mission: To reduce the burden of cardiovascular disease.
Our mission: To reduce the burden of cardiovascular disease.